Latest media releases


UBS Hosts Global Specialty Pharmaceuticals Conference

New York | | Media Releases Americas

The UBS Global Pharmaceuticals Conference begins today at the Grand Hyatt in New York City and runs through tomorrow, April 25. More than 1,000 portfolio managers, analysts, and investors are scheduled to attend.

The conference features presentations by senior executives from a comprehensive group of drug delivery, generic and other pharmaceutical companies representing over 80 pharmaceutical firms from 12 different countries.

Pharmaceuticals continue to be one of the most rapidly growing sectors in healthcare and 2006 will undoubtedly be another promising year as consolidation and differentiations continue within the sector. The conference will feature will address key therapeutic topics as well as legislative and regulatory issues that continue to impact the pharmaceutical industry.

Acadia
Acambis plc
Aeterna Zentaris
Akorn, Inc.
Alkermes, Inc.
Alliant Pharmaceuticals
Alpharma
American Pharmaceutical Partners, Inc.
Angiotech Pharmaceuticals, Inc.
Antares
Arena Pharmaceuticals
Asiapharma
Auxilium
AVI BioPharma
Axcan Pharma Inc.
Barr Pharmaceuticals, Inc.
Barrier Therapeutics, Inc.
Bavarian Nordic Research A/S
Bentley Pharmaceuticals, Inc.
Biocryst
Bioenvision, Inc.
Biovail Corporation
Cardiome Pharma Corp.
CoTherix
Cytrx
DOV Pharmaceuticals, Inc
Durect Corporation
Encysive Pharmaceuticals Inc.
Endo Pharmaceuticals Holdings Inc.
Enzon Pharmaceuticals, Inc.
Eurand S.p.A.
Flamel Technologies S.A.
Geron Corporation
Hi-Tech Pharmacal Co., Inc.
Hythiam
Icagen, Inc.
Indevus
Iomai
Jubilant Organosys Ltd.
Kalbe Farma
King Pharmaceuticals, Inc.
K-V Pharmaceutical Company
LaboPharm Inc.
MannKind Corporation
MGI Pharma, Inc.
Nabi Biopharmaceuticals
Nastech Pharmaceutical Company Inc.
Neose Technologies, Inc.
Neurochem Inc.
New River Pharmaceuticals Inc.
Northfield Laboratories Inc.
Novavax, Inc.
Noven Pharmaceuticals, Inc.
NPS Pharmaceuticals
Ovation Pharmaceutical, Inc.
Pain Therapeutics, Inc.
Paladin Labs, Inc.
Par Pharmaceutical Companies
Pharmion Corporation
Pozen, Inc.
Progenics Pharmaceuticals, Inc.
Prometheus Laboratories Inc.
pSivida
Ranbaxy Laboratories Limited
Salix Pharmaceuticals, Ltd.
Santarus, Inc.
Savient Pharmaceuticals, Inc.
ScinoPharm Taiwan, Ltd.
Scolr
Sepracor Inc.
Shanghai Fosun Pharmaceutical Group
Sirna
SkyePharma PLC
Somaxon Pharmaceuticals, Inc.
Sun Pharmaceuticals Industries
SuperGen, Inc.
The Medicines Company
Valera Pharmaceuticals Inc.
Xanodyne





Online conference information
To access audio transmissions and the conference agenda please go to the UBS Investment Bank website at www.ibb.ubs.com. Audio transmissions of company presentations will be available live and by replay. Replays will begin three hours after the actual presentation time and will be available on the site for four weeks.

UBS Investment Bank is a business group of UBS AG (NYSE: UBS), one of the world's leading financial firms. The investment banking and securities business is among the select bracket of major global houses, providing a full range of products to institutional and corporate clients, intermediaries, governments and hedge funds. UBS employs around 69,500 people in 50 countries and is listed on the New York, Tokyo and Zurich stock exchanges.


Inquiries: Allison Chin-Leong +1-212-882-5693 (office)


New York , April 24, 2006
UBS